Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Sangamo Therapeutics Inc’s stock clocked out at $0.49, down -1.60% from its previous closing price of $0.5. In other words, the price has decreased by -$1.60 from its previous closing price. On the day, 3.2 million shares were traded. SGMO stock price reached its highest trading level at $0.5125 during the session, while it also had its lowest trading level at $0.4851.
Ratios:
To gain a deeper understanding of SGMO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 0.76. In the meantime, Its Debt-to-Equity ratio is 5.07 whereas as Long-Term Debt/Eq ratio is at 5.07.
On December 10, 2024, H.C. Wainwright reiterated its Buy ratingand also kept the price unchanged to $10.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on November 03, 2023, whereas the target price for the stock was revised from $6 to $2.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGMO now has a Market Capitalization of 120737784 and an Enterprise Value of 125909280. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.89 while its Price-to-Book (P/B) ratio in mrq is 22.60. Its current Enterprise Value per Revenue stands at 1.975 whereas that against EBITDA is -1.655.
Stock Price History:
The Beta on a monthly basis for SGMO is 1.19, which has changed by 0.13953483 over the last 52 weeks, in comparison to a change of 0.1116153 over the same period for the S&P500. Over the past 52 weeks, SGMO has reached a high of $3.18, while it has fallen to a 52-week low of $0.37. The 50-Day Moving Average of the stock is -8.09%, while the 200-Day Moving Average is calculated to be -56.60%.
Shares Statistics:
It appears that SGMO traded 5.02M shares on average per day over the past three months and 3550580 shares per day over the past ten days. A total of 245.40M shares are outstanding, with a floating share count of 237.64M. Insiders hold about 3.16% of the company’s shares, while institutions hold 21.44% stake in the company. Shares short for SGMO as of 1749772800 were 25671043 with a Short Ratio of 4.81, compared to 1747267200 on 31907099. Therefore, it implies a Short% of Shares Outstanding of 25671043 and a Short% of Float of 10.569999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Sangamo Therapeutics Inc (SGMO) reflects the combined expertise of 2.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.11 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.44 and -$0.54 for the fiscal current year, implying an average EPS of -$0.49. EPS for the following year is -$0.38, with 2.0 analysts recommending between -$0.35 and -$0.4.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $31.68M. It ranges from a high estimate of $100M to a low estimate of $400k. As of the current estimate, Sangamo Therapeutics Inc’s year-ago sales were $356k
A total of 5 analysts have provided revenue estimates for SGMO’s current fiscal year. The highest revenue estimate was $106.4M, while the lowest revenue estimate was $20.8M, resulting in an average revenue estimate of $57.68M. In the same quarter a year ago, actual revenue was $57.8MBased on 5 analysts’ estimates, the company’s revenue will be $50.02M in the next fiscal year. The high estimate is $114.2M and the low estimate is $9.9M.
